TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today cardiovascular roundup published Oct. 27, 2026, highlighted research suggesting the LDL-lowering drug obicetrapib may also help protect against diabetes, though the report does not provide trial details. Edwards Lifesciences said the FDA approved its Pascal Precision system for tricuspid transcatheter edge-to-edge repair, a separate regulatory development. The roundup also covered new clearances and studies across cardiovascular care.
A cardiovascular news roundup published by MedPage Today on Oct. 27, 2026, reported two developments: research suggesting that the LDL-lowering drug obicetrapib may also protect against diabetes, and Edwards Lifesciences’ statement that the FDA approved its Pascal Precision device for tricuspid transcatheter edge-to-edge repair (TEER). The diabetes finding is presented as a potential benefit, while the device approval is attributed to the company.
The roundup described obicetrapib as a CETP inhibitor previously shown to lower LDL cholesterol and said it may offer protection against diabetes. It cited the European Journal of Preventive Cardiology but did not provide the study design, participant numbers, size of any effect, or whether the finding came from a randomized trial. The report therefore identifies a research signal, not proof that the medicine prevents diabetes or a new approved use.
Separately, Edwards Lifesciences said the FDA approved Pascal Precision for TEER of the tricuspid valve. TEER is a catheter-based procedure intended to repair a valve without open surgery. The supplied report does not specify the approved patient group, the evidence reviewed by regulators, or whether the approval changes clinical practice immediately.
The roundup also noted FDA clearances for two other products: Penumbra’s Lightning Flash computer-assisted vacuum thrombectomy system for deep vein thrombosis, and Elucid’s FFR-IQ software, which estimates fractional flow reserve noninvasively from coronary CT angiography. These are distinct regulatory actions and should not be confused with the Pascal approval or the obicetrapib research finding.
Potential Gains in Prevention and Repair
If later studies confirm a diabetes-related benefit, obicetrapib could have relevance beyond cholesterol management for people at elevated cardiovascular risk. But the source report provides no effect size or clinical details, so readers cannot judge how meaningful the finding is, which patients it might apply to, or whether it would alter prescribing. The distinction between a possible association or study outcome and a demonstrated preventive effect matters: the reported finding does not establish that obicetrapib prevents diabetes.
The Pascal Precision approval, as reported by Edwards, is a separate development for treatment of tricuspid valve disease. A regulatory authorization may make a device available for a defined use, but the practical impact depends on the approved indication, clinical evidence, clinician experience and access. The roundup supplies too little detail to assess those factors. Together, the items show how cardiovascular care advances through both drug research and device regulation, while each still requires careful attention to the evidence and intended use.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
OMRON VIVA 360+ Body Composition Monitor and Smart Scale
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
Two Separate Cardiovascular Developments
The source is a brief news roundup, not a full account of either the obicetrapib research or the FDA’s review of Pascal Precision. It places the developments among a broader set of cardiovascular stories, including studies of vaping and vascular function, statin treatment and thymic output, cannabis legalization and cardiovascular hospitalizations, and sleep-disordered breathing after stroke. Those items are separate reports and do not establish a connection to the two developments highlighted here.
MedPage Today’s item attributes the obicetrapib finding to the European Journal of Preventive Cardiology and the device-approval announcement to Edwards Lifesciences. It also references a report that cardiologist Ilija Srdanović was among student-backed leaders in Serbia who won a snap parliamentary election, with some expecting him to become prime minister. The roundup does not confirm that appointment; it is a separate political item rather than a medical development.
“The FDA approved the Pascal Precision device for transcatheter edge-to-edge repair of the tricuspid valve.”
— Edwards Lifesciences, as reported by MedPage Today
Evidence and Approval Details Missing
The roundup does not identify the obicetrapib study’s design, sample size, duration, diabetes outcomes, or the strength of the reported association. It is also unclear whether the result was a prespecified finding, whether it has been replicated, and whether researchers observed a direct protective effect. Until those details are available, the finding should be treated as preliminary or potential, not as evidence that patients should start or change treatment to prevent diabetes.
For Pascal Precision, the source does not state the FDA-approved indication, eligibility criteria, safety information, or the evidence supporting authorization. The report also gives no information about availability or adoption by hospitals. The election item does not confirm whether Srdanović has been formally selected as Serbia’s prime minister. These gaps limit what can be concluded from the brief roundup.
Full Study and Device Guidance
Readers will need the full European Journal of Preventive Cardiology paper to assess the obicetrapib finding, including its methods, results and limitations. Further research would be needed to establish whether any diabetes-related effect is reliable and clinically meaningful. The roundup does not report a planned publication, trial milestone or change to prescribing guidance.
For the Pascal Precision system, the next practical details would come from the FDA’s formal approval information and Edwards’ instructions on the authorized use, patient selection and availability. Clinicians and hospitals will need those specifics to determine where the device fits in care. No timetable or additional regulatory milestone was included in the source report.
Key Questions
Does the report show that obicetrapib prevents diabetes?
No. It says the drug may protect against diabetes, but provides no study methods or results. The finding does not establish prevention or a new treatment indication.
What is Pascal Precision approved to do?
Edwards Lifesciences said the FDA approved it for tricuspid transcatheter edge-to-edge repair. The roundup does not give the authorized patient group or other approval conditions.
What is tricuspid TEER?
TEER is a catheter-based procedure that repairs a heart valve by bringing tissue edges together. The source identifies the tricuspid valve but does not describe the device procedure or clinical evidence in detail.
Were other cardiovascular products mentioned?
Yes. The roundup reported FDA clearance of Penumbra’s Lightning Flash system for deep vein thrombosis and Elucid’s FFR-IQ software for estimating fractional flow reserve from coronary CT angiography. These were separate regulatory actions.
Has cardiologist Ilija Srdanović become Serbia’s prime minister?
The source does not confirm an appointment. It says some expect him to take the role after a snap parliamentary election; that remains an expectation in the report.
Source: medpagetoday.com
